Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

AH NEWS TODAY

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.

The deal includes up to 100% of future annual license fees ranging from $5 million to $40 million per year and a mid-double-digit percentage of Editas Medicine's portion of a potential $50 million contingent upfront payment from Vertex. Editas Medicine retains rights to fixed annual license fees for 2024 and a mid-single-digit million-dollar payment upon Vertex achieving certain annual sales milestones.

This agreement follows Editas Medicine's December 2023 non-exclusive license to Vertex for Cas9 gene editing technology in sickle cell disease and beta thalassemia treatments, including CASGEVY®.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
2
+0
1
Translate
Report
6304 Views
Comment
Sign in to post a comment
  • TranceHead : thought you weren't going to be on today my friend. Take care and look after yourself. i look forward to your posts on your return. hoping you get a bill of clean health.

Spread kindness and love. Life is short. Don’t let greed eat you.
2329Followers
106Following
24KVisitors
Follow